Literature DB >> 3939542

Presence in human cells and tissues of two prolidases and their alteration in prolidase deficiency.

J Butterworth, D A Priestman.   

Abstract

Two forms of prolidase can be separated for all the human cells and tissues examined by DEAE-cellulose column chromatography or batch methods. Serum had a very low prolidase activity eluting as a single peak prior to tissue peak I prolidase. Analysis of the two peaks can readily be carried out using white blood cells, cultured skin fibroblasts and amniotic fluid cells. Dialysis inactivated peak II prolidase although the loss can be prevented by the presence of dithiothreitol. The two peaks differed in their response to Mn(2+), substrate specificity, heat stability and inhibition by p-hydroxymercuribenzoate. In two unrelated cases of prolidase deficiency, fibroblast peak I was markedly reduced, although still detectable, whereas peak II was active against all the substrates, except for a 90% reduction against glycyl-L-proline. The properties of peak II were altered in the disease. The results imply that the two forms of prolidase are structurally related.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3939542     DOI: 10.1007/bf01805434

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  14 in total

1.  Partial purification and specificity of iminodipeptidase.

Authors:  N C DAVIS; E L SMITH
Journal:  J Biol Chem       Date:  1953-01       Impact factor: 5.157

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Prolidase deficiency: characteristics of human skin fibroblast prolidase using colorimetric and fluorimetric assays.

Authors:  D A Priestman; J Butterworth
Journal:  Clin Chim Acta       Date:  1984-09-29       Impact factor: 3.786

4.  Fluorimetric assay for prolinase and partial characterisation in cultured skin fibroblasts.

Authors:  J Butterworth; D Priestman
Journal:  Clin Chim Acta       Date:  1982-06-16       Impact factor: 3.786

5.  How to analyze binding, enzyme and uptake data: the simplest case, a single phase.

Authors:  J A Zivin; D R Waud
Journal:  Life Sci       Date:  1982-04-26       Impact factor: 5.037

6.  Substrate specificity of manganese-activated prolidase in control and prolidase-deficient cultured skin fibroblasts.

Authors:  J Butterworth; D Priestman
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

7.  Human erythrocyte prolidase and prolidase deficiency.

Authors:  F Endo; I Matsuda; A Ogata; S Tanaka
Journal:  Pediatr Res       Date:  1982-03       Impact factor: 3.756

8.  Effects of Econazole, Fungizone and Pimafucin on cell growth, lysosomal enzyme activity and sulphate metabolism of cultured human skin fibroblasts and amniotic fluid cells.

Authors:  J Butterworth
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

9.  Prolidase and prolidase deficiency.

Authors:  I Myara; C Charpentier; A Lemonnier
Journal:  Life Sci       Date:  1984-05-21       Impact factor: 5.037

10.  Prolidase deficiency.

Authors:  P S Pedersen; E Christensen; N J Brandt
Journal:  Acta Paediatr Scand       Date:  1983-09
View more
  8 in total

1.  Biochemical basis of prolidase deficiency. Polypeptide and RNA phenotypes and the relation to clinical phenotypes.

Authors:  F Endo; A Tanoue; A Kitano; J Arata; D M Danks; C M Lapière; Y Sei; S K Wadman; I Matsuda
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

2.  Expression and molecular analysis of mutations in prolidase deficiency.

Authors:  P Ledoux; C R Scriver; P Hechtman
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

3.  Deduced amino acid sequence of human prolidase and molecular analyses of prolidase deficiency.

Authors:  F Endo; A Tanoue; A Hata; A Kitano; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

4.  Molecular defect in siblings with prolidase deficiency and absence or presence of clinical symptoms. A 0.8-kb deletion with breakpoints at the short, direct repeat in the PEPD gene and synthesis of abnormal messenger RNA and inactive polypeptide.

Authors:  A Tanoue; F Endo; I Akaboshi; T Oono; J Arata; I Matsuda
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

5.  Prolidase could act as a diagnosis and treatment mediator in lung fibrosis.

Authors:  Ibrahim Türkbeyler; Tuncer Demir; Yavuz Pehlivan; Davut Sinan Kaplan; Ali Osman Ceribasi; Mustafa Orkmez; Nurten Aksoy; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

6.  Prolinase activity in prolidase-deficient fibroblasts.

Authors:  G Miech; I Myara; M Mangeot; V Voigtlander; A Lemonnier
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

7.  A plasma proteolysis pathway comprising blood coagulation proteases.

Authors:  Lu Yang; Yun Li; Arup Bhattacharya; Yuesheng Zhang
Journal:  Oncotarget       Date:  2016-07-05

8.  Quantitative analysis of the natural history of prolidase deficiency: description of 17 families and systematic review of published cases.

Authors:  Francis Rossignol; Marvid S Duarte Moreno; Carlos R Ferreira; Manuel Schiff; Jean-François Benoist; Manfred Boehm; Emmanuelle Bourrat; Aline Cano; Brigitte Chabrol; Claudine Cosson; José Luís Dapena Díaz; Arthur D'Harlingue; David Dimmock; Alexandra F Freeman; María Tallón García; Cheryl Garganta; Tobias Goerge; Sara S Halbach; Jan de Laffolie; Christina T Lam; Ludovic Martin; Esmeralda Martins; Andrea Meinhardt; Isabelle Melki; Amanda K Ombrello; Noémie Pérez; Dulce Quelhas; Anna Scott; Anne M Slavotinek; Ana Rita Soares; Sarah L Stein; Kira Süßmuth; Jenny Thies
Journal:  Genet Med       Date:  2021-05-26       Impact factor: 8.822

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.